STAG2-mutant glioblastoma cells have been previously shown to be sensitive to PARP inhibition in vitro (31, 46), and cohesin mutations may be potential biomarkers of PARP sensitivity in bladder cancer and Ewing sarcoma, where these mutations are common. This evidence concerns the gene PARP1 and Ewing sarcoma.